Table 2. Stereotactic dose prescriptions and outcomes.
| Pt. No. | Month of re-irradiation | Time since previous RT (months) | TV (mm3)a | Doseb | PI (%) | ECOG after one month | Subjective Improvementc | Survival in months after Re-RT |
|---|---|---|---|---|---|---|---|---|
| 1 | Sep 2009 | 21 | 33015 | 20 Gy (5 Fx) | 78 | 2 | Yes | Died at six months |
| 2 | Mar 2010 | 13 | 30056 | 25 Gy (5 Fx) | 82 | 3 | Yes | Died at three monthse |
| 3 | Mar 2010 | 12 | 39180 | 20 Gy (5 Fx) | 72 | 2 | No | Alive after 36 monthsf |
| 4 | Sep 2010d | 22 | 46459 | 16 Gy (2 Fx)+ | 85 | 1 | Yes | Died at 14 months |
| 5 | Jul 2012 | 26 | 54883 | 20 Gy (5 Fx) | 79 | 1 | Yes | Alive at 12 months |
RT, radiotherapy; PI, prescription isodose line; ECOG, Eastern Cooperative Oncology Group performance status.
a
Target volume in cubic millimetres.
b
Doses in Gy in continuous daily fractions.
c
No formal questionnaires were used to assess ‘subjective improvement’. Patient/associate satisfaction at first month post re-irradiation is presented.
d
Patient no. 4 required further whole-brain RT in view of multiple lesions consistent with glioblastoma multiforme.
e
Patient died at three months due to complications of diabetes mellitus.
f
Patient although alive at 30 months, however, has now suffered another relapse in the brainstem and cerebellum.